Advertisement

Advertisement

2024 JADPRO Live

hematologic malignancies

By The ASCO Post Staff / 2024 JADPRO Live

Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide

Justin Arnall, PharmD, BCOP, FCCP, of Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, discusses his JADPRO Live presentation on critical considerations when planning for cancer-...

Hematologic Malignancies

By Caroline Helwick / December 10, 2024 / 2024 JADPRO Live

Understanding the Assessment and Treatment of High-Risk Myelofibrosis

At the 2024 JADPRO Live event, which is held annually for advanced practitioners in oncology, high-risk myelofibrosis was a featured topic. “The treatment landscape has developed so much that JADPRO...

Advertisement

Advertisement

Dec

11

Today In Oncology

Imlunestrant Alone and Combined With Abemaciclib Effective in ESR1-Mutated Breast Cancer

BRCA-Mutation Carriers With Prior Diagnosis of Early-Onset Breast Cancer May Benefit From Risk-Reducing Surgery

Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL

Combination of Two Oral Agents May Improve Progression Free Survival in Patients With Previously Untreated CLL

Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant

Advertisement

© 2024 HSP News Service, L.L.C.